# FT538 in Subjects With Advanced Hematologic Malignancies

> **NCT04614636** · PHASE1 · TERMINATED · sponsor: **Fate Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- AML, Adult
- Multiple Myeloma
- Myeloma

## Interventions

- **DRUG:** FT538
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Daratumumab
- **DRUG:** Elotuzumab

## Key facts

- **NCT ID:** NCT04614636
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-17
- **Primary completion:** 2023-07-13
- **Final completion:** 2023-08-08
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** This study was terminated by the Sponsor.
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614636, "FT538 in Subjects With Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04614636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*